GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02182778 |
Recruitment Status :
Completed
First Posted : July 8, 2014
Last Update Posted : February 21, 2019
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Biliary Tract Cancer | Drug: Gemcitabine/Cisplatin Drug: Gemcitabine/Cisplatin /S-1 | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 246 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomized Phase III Trial Comparing Gemcitabine/Cisplatin/S-1 With Gemcitabine/Cisplatin for Unresectable Biliary Tract Cancer |
Actual Study Start Date : | July 9, 2014 |
Actual Primary Completion Date : | February 4, 2016 |
Actual Study Completion Date : | April 16, 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: Gemcitabine/Cisplatin group
Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
|
Drug: Gemcitabine/Cisplatin /S-1
S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
Other Name: Gemcitabine;gemzer, Cisplatin;Cispulan S-1;TS-1, |
Experimental: Gemcitabine/Cisplatin /S-1 group
S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
|
Drug: Gemcitabine/Cisplatin
Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
Other Name: Gemcitabine;gemzer, Cisplatin;Cispulan |
- Overall survival rate [ Time Frame: Probability of 1-year survival (%) ]The primary endpoint is designated to evaluate overall survival rate at 12-month.
- Response rate [ Time Frame: Every 3 months, up to 24 months ]The investigators will conduct CT test every 3 months in order to measure the tumor size of each patient and evaluate the best tumor response according to RECIST criteria.
- Progression free survival [ Time Frame: Every 3 months, up to 24 months ]In oredr to research the progression survival, the investigators will check the presence of progression disease for each patient every three months.
- Number of Participants with Adverse Events as a Measure of Safety [ Time Frame: 24 months ]The investigators will examine the frequency and the degree of each side effect that will appear to the patient at each course of chemotherapy .
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with cytologically or histologically proved biliary tract cancer
- age >=20 years
- Performance Status (PS) 0-2
- No prior history of chemotherapy or radiotherapy.
- Adequate bone marrow function (neutrophil count >=1,500/mm3, and platelet count >=100,000/mm3), liver function (total bilirubin >=3 mg/dL and AST/ALT >=150 IU/L), and renal function (creatinine clearance >=45 mL/min)
- Adequate oral intake
- Provided written informed consent -
Exclusion Criteria:
- Patients with interstitial pneumonia or pulmonary fibrosis
- Patients with uncontrollable diabetes mellitus, liver disease, angina pectoris or a new onset of myocardial infarction within 3 months
- Patients with severe active infection
- Patients with moderate or marked pleural effusion or ascites necessitating drainage
- Patients with a history of severe drug allergy
- Patients with other serious comorbid disease
- Patients who are pregnant or lactating, or have an intention to get pregnant
- Patients with mental disease
-
Patients who are judged inappropriate for the entry into the study by the principle doctor
-
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02182778
Japan | |
Kyoto University Hospital | |
Kyoto, Japan, 606-8507 |
Study Director: | Masashi Kanai | Kyoto University |
Responsible Party: | Kansai Hepatobiliary Oncology Group |
ClinicalTrials.gov Identifier: | NCT02182778 |
Other Study ID Numbers: |
KHBO1401 UMIN 000014371 ( Registry Identifier: UMIN ) |
First Posted: | July 8, 2014 Key Record Dates |
Last Update Posted: | February 21, 2019 |
Last Verified: | April 2018 |
Biliary Tract Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Biliary Tract Diseases Digestive System Diseases |
Cisplatin Gemcitabine Antineoplastic Agents Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action |